Skip to main content
Premium Trial:

Request an Annual Quote

IntegraGen, Pompidou Hospital to Develop Sequencing Methods

NEW YORK (GenomeWeb) – IntegraGen and the Georges Pompidou European Hospital (HEGP) today announced an agreement to develop high-throughput sequencing methods. 

Clinicians and biologists at the hospital will use the new methods along with bioinformatic analysis techniques jointly developed by the partners in order to rapidly interpret genomic data. The technologies will enable patients, particularly those with cancer tumors, to be rapidly prescribed targeted therapies, IntegraGen and HEGP said. 

The deal will allow oncologists and biologists at Paris-based HEGP to "benefit from the latest genome sequencing technologies and … to develop specific tools for interpreting results which enable the personalized care of patients," Pierre Laurent-Puig, an oncology biologist at the hospital, said in a statement. "This will result in a better ability to diagnose and treat each patient on an individual basis, depending on the genetic markers identified in their tumor." 

HEGP operates under the aegis of the public hospital system of the city of Paris and its suburbs.

The Scan

New Study Investigates Genomics of Fanconi Anemia Repair Pathway in Cancer

A Rockefeller University team reports in Nature that FA repair deficiency leads to structural variants that can contribute to genomic instability.

Study Reveals Potential Sex-Specific Role for Noncoding RNA in Depression

A long, noncoding RNA called FEDORA appears to be a sex-specific regulator of major depressive disorder, affecting more women, researchers report in Science Advances.

New mRNA Vaccines Offer Hope for Fighting Malaria

A George Washington University-led team has developed mRNA vaccines for malaria that appear to provide protection in mice, as they report in NPJ Vaccines.

Unique Germline Variants Found Among Black Prostate Cancer Patients

Through an exome sequencing study appearing in JCO Precision Oncology, researchers have found unique pathogenic or likely pathogenic variants within a cohort of Black prostate cancer patients.